262 related articles for article (PubMed ID: 33004339)
1. TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors.
Cocco E; Lee JE; Kannan S; Schram AM; Won HH; Shifman S; Kulick A; Baldino L; Toska E; Arruabarrena-Aristorena A; Kittane S; Wu F; Cai Y; Arena S; Mussolin B; Kannan R; Vasan N; Gorelick AN; Berger MF; Novoplansky O; Jagadeeshan S; Liao Y; Rix U; Misale S; Taylor BS; Bardelli A; Hechtman JF; Hyman DM; Elkabets M; de Stanchina E; Verma CS; Ventura A; Drilon A; Scaltriti M
Cancer Discov; 2021 Jan; 11(1):126-141. PubMed ID: 33004339
[TBL] [Abstract][Full Text] [Related]
2. JND4135, a New Type II TRK Inhibitor, Overcomes TRK xDFG and Other Mutation Resistance In Vitro and In Vivo.
Wang J; Zhou Y; Tang X; Yu X; Wang Y; Chan S; Song X; Tu Z; Zhang Z; Lu X; Zhang Z; Ding K
Molecules; 2022 Oct; 27(19):. PubMed ID: 36235036
[TBL] [Abstract][Full Text] [Related]
3. A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.
Drilon A; Nagasubramanian R; Blake JF; Ku N; Tuch BB; Ebata K; Smith S; Lauriault V; Kolakowski GR; Brandhuber BJ; Larsen PD; Bouhana KS; Winski SL; Hamor R; Wu WI; Parker A; Morales TH; Sullivan FX; DeWolf WE; Wollenberg LA; Gordon PR; Douglas-Lindsay DN; Scaltriti M; Benayed R; Raj S; Hanusch B; Schram AM; Jonsson P; Berger MF; Hechtman JF; Taylor BS; Andrews S; Rothenberg SM; Hyman DM
Cancer Discov; 2017 Sep; 7(9):963-972. PubMed ID: 28578312
[TBL] [Abstract][Full Text] [Related]
4. Switch type I to type II TRK inhibitors for combating clinical resistance induced by xDFG mutation for cancer therapy.
Xiang S; Wang J; Huang H; Wang Z; Song X; Zhou Y; Jin F; He X; Zhang ZM; Tu Z; Ding K; Zhang Z; Lu X
Eur J Med Chem; 2023 Jan; 245(Pt 1):114899. PubMed ID: 36410169
[TBL] [Abstract][Full Text] [Related]
5. Selective type II TRK inhibitors overcome xDFG mutation mediated acquired resistance to the second-generation inhibitors selitrectinib and repotrectinib.
Xiang S; Lu X
Acta Pharm Sin B; 2024 Feb; 14(2):517-532. PubMed ID: 38322338
[TBL] [Abstract][Full Text] [Related]
6. Discovery of the First Highly Selective and Broadly Effective Macrocycle-Based Type II TRK Inhibitors that Overcome Clinically Acquired Resistance.
Wang Z; Wang J; Wang Y; Xiang S; Song X; Tu Z; Zhou Y; Zhang ZM; Zhang Z; Ding K; Lu X
J Med Chem; 2022 Apr; 65(8):6325-6337. PubMed ID: 35426680
[TBL] [Abstract][Full Text] [Related]
7. Discovery of Next-Generation Tropomyosin Receptor Kinase Inhibitors for Combating Multiple Resistance Associated with Protein Mutation.
Zhuo LS; Wang MS; Wu FX; Xu HC; Gong Y; Yu ZC; Tian YG; Pang C; Hao GF; Huang W; Yang GF
J Med Chem; 2021 Oct; 64(20):15503-15514. PubMed ID: 34668694
[TBL] [Abstract][Full Text] [Related]
8. Structure-Based Optimization of the Third Generation Type II Macrocycle TRK Inhibitors with Improved Activity against Solvent-Front, xDFG, and Gatekeeper Mutations.
Wang Z; Wang J; Wang Y; Xiang S; Zhou H; Song S; Song X; Tu Z; Zhou Y; Ding K; Zhang ZM; Zhang Z; Lu X
J Med Chem; 2023 Sep; 66(18):12950-12965. PubMed ID: 37676745
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel 3-(1H-pyrazol-4-yl)-1H-indazole derivatives as potent type II TRK inhibitors against acquired resistance.
Qin Q; Guo Z; Lu S; Wang X; Fu Q; Wu T; Sun Y; Liu N; Zhang H; Zhao D; Cheng M
Eur J Med Chem; 2024 Jan; 264():115953. PubMed ID: 38029466
[TBL] [Abstract][Full Text] [Related]
10. NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors.
Somwar R; Hofmann NE; Smith B; Odintsov I; Vojnic M; Linkov I; Tam A; Khodos I; Mattar MS; de Stanchina E; Flynn D; Ladanyi M; Drilon A; Shinde U; Davare MA
Commun Biol; 2020 Dec; 3(1):776. PubMed ID: 33328556
[TBL] [Abstract][Full Text] [Related]
11. Discovery of 3-pyrazolyl-substituted pyrazolo[1,5-a]pyrimidine derivatives as potent TRK inhibitors to overcome clinically acquired resistance.
Gong Y; Wu FX; Wang MS; Xu HC; Zhuo LS; Yang GF; Huang W
Eur J Med Chem; 2022 Nov; 241():114654. PubMed ID: 35961071
[TBL] [Abstract][Full Text] [Related]
12. TRK inhibitors in TRK fusion-positive cancers.
Drilon A
Ann Oncol; 2019 Nov; 30 Suppl 8():viii23-viii30. PubMed ID: 32223935
[TBL] [Abstract][Full Text] [Related]
13. Discovery of (E)-N-(4-methyl-5-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thiazol-2-yl)-2-(4-methylpiperazin-1-yl)acetamide (IHMT-TRK-284) as a novel orally available type II TRK kinase inhibitor capable of overcoming multiple resistant mutants.
Wang B; Zhang W; Liu X; Zou F; Wang J; Liu Q; Wang A; Hu Z; Chen Y; Qi S; Jiang Z; Chen C; Hu C; Wang L; Wang W; Liu Q; Liu J
Eur J Med Chem; 2020 Dec; 207():112744. PubMed ID: 32949955
[TBL] [Abstract][Full Text] [Related]
14. Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.
Drilon A; Ou SI; Cho BC; Kim DW; Lee J; Lin JJ; Zhu VW; Ahn MJ; Camidge DR; Nguyen J; Zhai D; Deng W; Huang Z; Rogers E; Liu J; Whitten J; Lim JK; Stopatschinskaja S; Hyman DM; Doebele RC; Cui JJ; Shaw AT
Cancer Discov; 2018 Oct; 8(10):1227-1236. PubMed ID: 30093503
[TBL] [Abstract][Full Text] [Related]
15. Molecular Characteristics of Repotrectinib That Enable Potent Inhibition of TRK Fusion Proteins and Resistant Mutations.
Murray BW; Rogers E; Zhai D; Deng W; Chen X; Sprengeler PA; Zhang X; Graber A; Reich SH; Stopatschinskaja S; Solomon B; Besse B; Drilon A
Mol Cancer Ther; 2021 Dec; 20(12):2446-2456. PubMed ID: 34625502
[No Abstract] [Full Text] [Related]
16. Resistance to TRK inhibition mediated by convergent MAPK pathway activation.
Cocco E; Schram AM; Kulick A; Misale S; Won HH; Yaeger R; Razavi P; Ptashkin R; Hechtman JF; Toska E; Cownie J; Somwar R; Shifman S; Mattar M; Selçuklu SD; Samoila A; Guzman S; Tuch BB; Ebata K; de Stanchina E; Nagy RJ; Lanman RB; Houck-Loomis B; Patel JA; Berger MF; Ladanyi M; Hyman DM; Drilon A; Scaltriti M
Nat Med; 2019 Sep; 25(9):1422-1427. PubMed ID: 31406350
[TBL] [Abstract][Full Text] [Related]
17. NTRK fusion-positive cancers and TRK inhibitor therapy.
Cocco E; Scaltriti M; Drilon A
Nat Rev Clin Oncol; 2018 Dec; 15(12):731-747. PubMed ID: 30333516
[TBL] [Abstract][Full Text] [Related]
18. Selective TRK Inhibitor CH7057288 against TRK Fusion-Driven Cancer.
Tanaka H; Sase H; Tsukaguchi T; Hasegawa M; Tanimura H; Yoshida M; Sakata K; Fujii T; Tachibana Y; Takanashi K; Higashida A; Hasegawa K; Ono Y; Oikawa N; Mio T
Mol Cancer Ther; 2018 Dec; 17(12):2519-2529. PubMed ID: 30242093
[TBL] [Abstract][Full Text] [Related]
19. TRK inhibitor activity and resistance in TRK fusion-positive cancers in adults.
Harada G; Drilon A
Cancer Genet; 2022 Jun; 264-265():33-39. PubMed ID: 35334340
[TBL] [Abstract][Full Text] [Related]
20. Regulating Tumorigenicity and Cancer Metastasis through TRKA Signaling.
Fan Y; Zhang B; Du X; Wang B; Yan Q; Guo L; Yao W
Curr Cancer Drug Targets; 2024; 24(3):271-287. PubMed ID: 37670705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
